Biopharma PEG Scientific Inc articles

CAR-T cell therapy has transformed the treatment landscape for hematological cancers, yet its widespread adoption remains limited by the complexity of ex vivo manufacturing. Patient-specific cell collection, genetic modification, and reinfusion introduce high costs, long timelines, and scalability challenges.

To address these barriers, in vivo CAR-T has emerged as a new strategy—engineering T cells directly inside the patient using nucleic acid delivery systems. This approach has

In the fast-evolving field of antibody–drug conjugates (ADCs), linker chemistry plays a decisive role in defining therapeutic performance. The ability to control the drug-to-antibody ratio (DAR), conjugation site, and overall molecular stability directly impacts both efficacy and safety.

Among emerging linker materials, azide-functionalized PEG derivatives have become essential tools for CuAAC (copper-catalyzed) and SPAAC (strain-promoted) click conjugation. These bio-orthogonal

Antibody-drug conjugates (ADCs) combine potent small-molecule drugs with monoclonal antibodies for targeted cancer therapy. A major challenge is loading enough drug onto each antibody without compromising solubility or circulation time. Introducing polyethylene glycol (PEG) linkers between the antibody and drug payload can address this. PEG is hydrophilic, biologically inert, and FDA‐recognized as safe. As a flexible spacer, PEG “shields” the hydrophobic drug, greatly improving

Watertown, MA – March 24, 2025 – Biopharma PEG, a leading supplier of high-quality polyethylene glycol (PEG) derivatives, highlights its innovative product DSPE-PEG-Mannose, an advanced biomedical polymer with significant potential in drug delivery, tumor-targeted therapy, tissue recognition, and adhesion.

Structural Advantages of DSPE-PEG-Mannose

DSPE-PEG-Mannose is composed of three key components that enable its diverse applications:

l DSPE (1,2-Distearoyl-sn-gly

Watertown, MA, July 22, 2024  – Biopharma PEG, a top supplier of PEG derivatives, is excited to introduce its new line of monodispersed PEGs. These specially sized polymers are designed to improve the stability and delivery of proteins and peptides in drugs. They are essential for Antibody-Drug Conjugate (ADC) linkers, Proteolysis Targeting Chimeras (PROTAC) linkers, and PEGylated proteins and peptides.

PEGs as ADC Linkers

PEGs act as a shield around the ADC payload,

Biopharma PEG, a leading innovator in polyethylene glycol (PEG) derivatives, proudly introduces its featured Azide PEG series, which can be used in drug development, click chemistry, ADCs (Antibody Drug Conjugates), PROTACs (Proteolysis Targeting Chimeras), and beyond.

This Azide PEG features monodispersed PEGs such as N3-PEG4-OH, N3-PEG3-COOH, N3-PEG11-NH2, N3-PEG3-NHS ester, 2-((Azido-PEG8-carbamoyl)methoxy)acetic acid,

As of January 1, 2023, global vaccine development includes a total of 966 vaccine candidates, of which 23% (220) are traditional inactivated or attenuated vaccines. Advances in molecular technology have facilitated the development of other platforms, such as recombinant protein vaccines, nucleic acid vaccines, and viral vector vaccines, which have further diversified global vaccine development.

Recombinant protein vaccines accounted for the largest proportion of all pipeline in develop

What is "click chemistry"? "Click Chemistry", this is a literary name given to this kind of reaction by the Nobel Prize winner K.Burry Sharless, when the cards are put together, "click" (click). Simply put, it is to add two structures to two molecules respectively, and these two structures can be specifically combined to synthesize the required chemical molecules. One of the most famous click-chemistry reactions is the Cu-catalyzed azide-alkyne cycloaddition reaction (CuAAC reaction).

Structurally, an ADC consists of monoclonal antibodies (Antibody) that target specific antigens on tumor surfaces, cytotoxic drugs (drugs) that kill tumor cells, and linkers (Conjugate/ linkers) that conjugate cytotoxic drugs to antibodies.

The link between the antibody and linker is controll

PROTAC technology has been in development for more than 20 years. PROTAC proof-of-concept studies date back to 2001, when Crews' team tested the possibility of artificially induced intracellular protein degradation with a peptide that was too large in molecular weight and required cells to penetrate the peptide to improve cell permeability. The discovery of the first small molecule PROTAC and the subsequent small molecule E3 ligand, reported in 2008, greatly promoted the pursuit of PROTAC tec